CYP2C8 Inhibitors
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gemfibrozil 1-O-β-Glucuronide | 91683-38-4 | sc-221665C sc-221665 sc-221665-CW sc-221665A sc-221665B sc-221665B-CW sc-221665D sc-221665E | 500 µg 1 mg 1 mg 2 mg 5 mg 5 mg 10 mg 25 mg | $326.00 $500.00 $653.00 $842.00 $1581.00 $1734.00 $2856.00 $6050.00 | 2 | |
Gemfibrozil 1-O-β-Glucuronide (CAS 91683-38-4) is a metabolite of the drug gemfibrozil. It acts as an inhibitor of the Cytochrome P450 2C8 (CYP2C8) enzyme, which is involved in the metabolism of various drugs and endogenous compounds in the liver. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $65.00 $262.00 | 2 | |
Gemfibrozil acts as a competitive inhibitor of CYP2C8, directly interacting with the enzyme's active site to decrease the metabolism of substrates processed by this enzyme, leading to potential alterations in their pharmacokinetic profiles. | ||||||
Terfenadine | 50679-08-8 | sc-208421A sc-208421B sc-208421 | 500 mg 1 g 5 g | $43.00 $70.00 $118.00 | ||
Terfenadine exhibits distinctive interactions with CYP2C8, characterized by its ability to form stable complexes through π-π stacking and hydrophobic contacts. The compound's unique structural features enable selective binding, influencing the enzyme's catalytic efficiency. Its metabolic pathway involves intricate electron transfer mechanisms, which can alter reaction kinetics. Furthermore, terfenadine's conformational flexibility allows it to adapt within the active site, potentially affecting substrate turnover rates and enzyme regulation. | ||||||
Clopidogrel Acyl-β-D-glucuronide | 1314116-53-4 (S-isomer) | sc-217936 | 1 mg | $970.00 | 4 | |
Clopidogrel Acyl-β-D-glucuronide (CAS 1314116-53-4, S-isomer) is a metabolite of the drug clopidogrel. It acts as an inhibitor of the Cytochrome P450 2C8 (CYP2C8) enzyme. | ||||||
Trimethoprim | 738-70-5 | sc-203302 sc-203302A sc-203302B sc-203302C sc-203302D | 5 g 25 g 250 g 1 kg 5 kg | $66.00 $158.00 $204.00 $707.00 $3334.00 | 4 | |
Trimethoprim inhibits CYP2C8 through a mechanism that likely involves direct competition for the enzyme's active site, which can interfere with the normal metabolic processing of substrates by this enzyme. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $120.00 | 1 | |
Clopidogrel inhibits CYP2C8 activity through a mechanism that may involve the formation of a metabolite that interacts with the enzyme, leading to decreased metabolic processing of substrates that depend on this enzyme for clearance. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
2'-Deoxy-2',2'-difluorocytidine acts as an inhibitor of CYP2C8, potentially through direct interaction or competitive inhibition, affecting the enzyme's ability to metabolize other substrates, including those used in chemotherapy. | ||||||
Repaglinide | 135062-02-1 | sc-219959 sc-219959A sc-219959B | 100 mg 250 mg 1 g | $215.00 $414.00 $1331.00 | 3 | |
Repaglinide's inhibition of CYP2C8 can lead to reduced metabolic clearance of the drug itself and other substrates, potentially due to competitive inhibition or interaction with the enzyme's active site. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Taxol is known to inhibit CYP2C8, possibly through competitive interaction with the enzyme, which can affect the metabolic processing and pharmacokinetics of co-administered drugs metabolized by CYP2C8. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
Ritonavir exhibits inhibition of CYP2C8 among other cytochrome P450 enzymes, through a mechanism that may involve direct enzyme binding or the formation of metabolite-intermediate complexes that reduce enzyme activity. | ||||||